Alpha Teknova Sees Q3 2026 Revenue Of $12.5M-$12.7M, Up 19% - 21% YoY
Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today
Alpha Teknova expects to make about 19 to 21 percent more money next quarter. When a company grows its sales, it can hint that customers trust their products.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.